Phaarmasia Ltd. (BSE: 523620) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹59 Cr, it ranks #3,666 by market cap among the 6,197 Indian listed companies on FinBizNet, and #50 of 63 in Pharmaceuticals. At ₹79.25 (as of 16 Nov 2026), the share price is 39.8% below its 52-week high of ₹131.75 and 115.3% above its 52-week low of ₹36.81. The share price is up 133.1% over one year and down 6.3% over three months.
| Current Price | ₹79.25 |
|---|---|
| Market Cap | ₹59 Cr |
| BSE Code | 523620 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 3.3 |
| Return on Equity | 113.99% |
| Return on Assets | 5.57% |
| 52-Week Range | ₹36.81 – ₹131.75 |
| 1-Year Price Change | +133.1% |
| 3-Month Price Change | -6.3% |
| Beta (1Y) | 0.43 |
| Headquarters | Hyderabad, Telangana |
| Website | www.phaarmasia.in |
Delivery averaged 89.2% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Phaarmasia Limited manufactures and sells oral contraceptive pills and iron tablets in India. It offers hormone products, including mifepristone and misoprostaol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, fluoxymesterone, liothyronine sodium, chlorodehydromethyltestosterone, liothyronine sodium, oxandrolone tablets, testosterone cypionate, methenolone enanthate, drostanolone, testosterone, trenbolone, and stanozolol cypionate injections. The company provides herbal products, such as herbal toothpaste, cough and sore throat reliver, and mouth ulcer gel under the Smyle brand name. Phaarmasia Limited was incorporated in 1981 and is based in Hyderabad, India.
1. Pharmaceuticals-This segment engages in the manufacture and sale of pharmaceutical products primarily cosmetics and oral contraceptive pills.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Phaarmasia Ltd. | ₹59 Cr | 3.3 | 113.99% | — | +133.1% |
Listed by market capitalisation. Ratios are shown for context only.
Phaarmasia Ltd. is trading at ₹79.25, with a market capitalisation of ₹59 Cr.
Phaarmasia Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Phaarmasia Ltd. has a P/E of 3.3 and a return on equity of 113.99%.
Phaarmasia Ltd. is listed on the BSE under the scrip code 523620.
Phaarmasia Ltd.'s share price is up 133.1% over one year and down 6.3% over three months. Its 52-week range is ₹36.81 to ₹131.75.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.